Skip to Content

AHIP Comments on Insulin Caps Legislation

Press Release

Published Mar 31, 2022 • by AHIP

WASHINGTON, D.C. – (March 31, 2022) – For many patients, the excessive and unreasonable prices for prescription drugs have created an affordability crisis that threatens their health and well-being. Patients should have access to more affordably priced medications, including insulin. AHIP supports real solutions to drug affordability that deliver critically needed medicines, work for patients, address the lack of transparency in how pharmaceutical companies set and increase prices and deliver lower health insurance premiums and costs for all consumers.    

Insulin prices are too high because Big Pharma alone sets and controls the price. While health insurance providers work to reduce insulin costs, this policy unfortunately does nothing to lower the price of insulin but simply shifts costs to others through higher insurance premiums and copays. Rather than holding Big Pharma accountable, this legislation continues to empower Big Pharma to raise insulin prices with impunity leaving patients, businesses, and hardworking taxpayers paying even more for health care.

We’ll work with Congress and the Administration to find effective solutions to ensure that everyone gets the medication they need at a price they can afford.

About AHIP

AHIP is the national association whose members provide health care coverage, services, and solutions to hundreds of millions of Americans every day. We are committed to market-based solutions and public-private partnerships that make health care better and coverage more affordable and accessible for everyone. Visit to learn how working together, we are Guiding Greater Health.